Your browser doesn't support javascript.
Multiplatform Assessment of Saliva for SARS-CoV-2 Molecular Detection in Symptomatic Healthcare Personnel and Patients Presenting to the Emergency Department.
Potter, Robert F; Ransom, Eric M; Wallace, Meghan A; Johnson, Caitlin; Kwon, Jennie H; Babcock, Hilary M; Eby, Charles S; Anderson, Neil W; Parikh, Bijal A; Burnham, Carey-Ann D.
  • Potter RF; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Ransom EM; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Wallace MA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Johnson C; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Kwon JH; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Babcock HM; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Eby CS; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Anderson NW; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Parikh BA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Burnham CD; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
J Appl Lab Med ; 7(3): 727-736, 2022 05 04.
Article in English | MEDLINE | ID: covidwho-1398106
ABSTRACT

BACKGROUND:

Saliva has garnered great interest as an alternative specimen type for molecular detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Data are limited on the relative performance of different molecular methods using saliva specimens and the relative sensitivity of saliva to nasopharyngeal (NP) swabs.

METHODS:

To address the gap in knowledge, we enrolled symptomatic healthcare personnel (n = 250) from Barnes-Jewish Hospital/Washington University Medical Center and patients presenting to the Emergency Department with clinical symptoms compatible with coronavirus disease 2019 (COVID-19; n = 292). We collected paired saliva specimens and NP swabs. The Lyra SARS-CoV-2 assay (Quidel) was evaluated on paired saliva and NP samples. Subsequently we compared the Simplexa COVID-19 Direct Kit (Diasorin) and a modified SalivaDirect (Yale) assay on a subset of positive and negative saliva specimens.

RESULTS:

The positive percent agreement (PPA) between saliva and NP samples using the Lyra SARS-CoV-2 assay was 63.2%. Saliva samples had higher SARS-CoV-2 cycle threshold values compared to NP swabs (P < 0.0001). We found a 76.47% (26/34) PPA for Simplexa COVID-19 Direct Kit on saliva and a 67.6% (23/34) PPA for SalivaDirect compared to NP swab results.

CONCLUSION:

These data demonstrate molecular assays have variability in performance for detection of SARS-CoV-2 in saliva.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Prognostic study Limits: Humans Language: English Journal: J Appl Lab Med Year: 2022 Document Type: Article Affiliation country: Jalm

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Prognostic study Limits: Humans Language: English Journal: J Appl Lab Med Year: 2022 Document Type: Article Affiliation country: Jalm